KMO (Kynurenine 3-monooxygenase) is an enzyme that plays a key role in the kynurenine pathway, responsible for metabolizing the amino acid tryptophan. It helps regulate the balance of metabolites within this pathway, influencing processes that can affect brain health. KMO activity has been linked to neurological conditions such as Alzheimer’s disease, Huntington’s disease, and schizophrenia.
Testing KMO activity can be particularly beneficial for:
Dysregulated KMO activity can lead to an imbalance in the kynurenine pathway, potentially resulting in various symptoms, particularly related to neurological and mental health:
Several factors can impact the activity of KMO:
Regulating KMO activity typically involves addressing the broader factors that influence the kynurenine pathway: